Carrie Wade joined British American Tobacco charged with contributing to Regulatory Scientific Engagement efforts within Corporate and Regulatory Affairs. Previous to joining BAT in 2025, Carrie worked in Global Scientific Engagement at Philip Morris International in Lausanne and led the Harm Reduction Policy program at R Street Institute in Washington DC.

Her academic background in the biological mechanisms of opioid addiction has informed her work in public health and harm reduction – her commitment to evidence-based drug policy was further strengthen during her time spent at the Baltimore Harm Reduction Coalition and Johns Hopkins University, Bloomberg School of Public Health. Her research and work has been published across leading scientific journals, book chapters and media outlets.